It is responsible for 1 major technological project funded by the National Health Commission of China, as well as 20+ other key technological projects at the provincial and ministerial levels in China.
It has obtained 80+ patents, 92 CE certificates, and 150+ papers in SCI and core journals. Meanwhile, in the formulation of 2 national standards, 1 industry standard, 1 group standard, and 1 national standard material, co-edited 10 books and 2 consensus guidelines.
It pioneered the "5G+ panel testing“ protocol for fungal diseases in the industry, and several of its products have achieved domestic substitution and technological advancement.
Products have been introduced to over 1,200 medical institutions in 34 provincial-level administrative regions in China and are promoted to over 80 countries and regions across Asia, Europe, South America, and North America.
Recognition from the World Health Organization (WHO) with 6 fungal detection kits selected for the global recommended list.
G and GM test kits approved by the New York State Department of Health Clinical Laboratory Evaluation Program.
Top 50 companies with independent innovation in the pharmaceutical industry in 2024.
Passed the national patent-intensive product certification and received support from Tianjin's special funds for high-quality development of the manufacturing industry.
Awarded the title of "China's Independent Innovation Brand," Dynamiker Pets Biotechnology (Tianjin) Co., Ltd. was established.
It has been rated as a national key specialized and innovative "little giant" enterprise and obtained the certification of "AEO Advanced Enterprise".
Many awards have been given for positive contributions to the prevention and control of the COVID-19 pandemic.
It has received support from the National Major Science and Technology Special Project for the Prevention and Control of Infectious Diseases and has been awarded the title of Gazelle Enterprise.
7 products passed the German TUV review and obtained CE certification.
G test was recognized as a "Specialized, Fined, Peculiar and Innovative" product.
G test research results were rated as the world's top 10 in the field of fungi by the ECCMID.
Product listed in "Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline".
Research on the diagnosis and treatment of candidemia with Iran, the Netherlands, and Oman based on "Belt and Road" Policy.
Passed ISO13485 certification.
The G test product successfully entered the UK, and the GM test product passed the clinical verification in Brazil.
Partnered with GAFFI (Global Action Foundation for Fungal Infections) to promote Project 95/95.
Product's clinical research was published at TIMM and included in the 2015 European and 2016 American guidelines.
Dynamiker was established, completed GMP and received CE certification for 9 products.
Dynamiker has been an important member since 2019, when the policy of establishing a national fungal disease surveillance network was established.
We hope to reach the goal of getting patients with invasive fungal disease diagnosed and treated.
Dynamiker provides diagnostic kits and Pfizer provides drugs to jointly fight invasive fungal infections.
Dynamiker provides financial support for the development of "Aspergillus Website and Aspergillus Website for Patients," which aims to provide educational information and support to patients, physicians, and scientists dealing with Aspergillus infections.
